Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.
Request Insights
IN THE NEWSMay 04, 2021: Teva Pharmaceutical Industries Ltd. announced the launch of its new Erythromycin tablets to treat or prevent a variety of bacterial infections.
February 27, 2020: GlaxoSmithKline plc (GSK) and Innoviva, Inc. announced the European Medicines Agency (EMA) approval of Trelegy Ellipta for the treatment of asthma in adults.
The global whooping cough treatment market is estimated to grow at a notable CAGR over the forecast period, i.e., 2022 – 2031. Whooping cough, also known as, pertussis, is a severe respiratory infection, common among children. The growth of the market can be attributed to the growing prevalence of whooping cough globally. According to the data by the World Health Organization (WHO), 151 074 cases of whooping cough were reported globally in 2018. The symptoms of whooping cough range from mild fever, runny nose and cough, to difficulty in breathing, whooping, and pneumonia. As the condition tends to be more severe for children, the rising pediatric population is estimated to boost the market growth. A report by the World Bank stated that the global population of children between 0 to 14 years reached 1.977 billion in 2020, up from 1.869 billion in 2010. Along with this, the growing health awareness among people, coupled with the adoption of advance treatment method, are anticipated to boost the market growth. Furthermore, high incidences of other lung and throat infections, including pharyngitis, and pneumonia, and rising pollution levels are also crucial factors supporting the growth of the market.
The market is segmented by patient type into pediatric, adolescents, adults, and others, out of which, the pediatric segment is anticipated to hold a substantial share in the global whooping cough treatment market over the forecast period on account of high incidences and higher severity of whooping cough amongst children. Mostly in case of children, whooping cough results in pneumonia, which is a major cause of children mortality. As per a WHO report, pneumonia accounts for 14% of all deaths of children under 5 years old every year. Moreover, pneumonia caused 740,180 deaths amongst children, in 2019.CLICK TO DOWNLOAD SAMPLE REPORT
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the global whooping cough treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of increasing pediatric population, along with growing availability of healthcare facilities in the developing regions. Moreover, the high prevalence of whooping cough in countries, such as, India, China, Japan, Philippines, Vietnam, and others, is further estimated to boost the market growth. According to the data by WHO, 12,566 cases of pertussis were reported in India, while 2,947 cases were reported in Japan, in 2020. The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the advanced healthcare technologies present in the region, along with the presence of major pharmaceutical companies.
The global whooping cough treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global whooping cough treatment market includes the following segments:
FREQUENTLY ASKED QUESTIONS
The increasing prevalence of whooping cough, especially amongst children, is estimated to boost the market growth.
The market is anticipated to attain a notable CAGR over the forecast period, i.e., 2022 – 2031.
Low availability of treatment facilities, such as, medical practitioners, and vaccines, in undeveloped regions are estimated to hamper the market growth.
The North America region is anticipated to provide more business opportunities over the forecast period owing to the advanced healthcare sector in the region.
The major players in the market are Pfizer Inc., Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Siemens Healthcare GmbH, Baxter International, Inc., and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by patient type, drug type, end-user, and by region.
The hospital segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions
Copyright © 2021 Research Nester. All Rights Reserved
